Search News Archives
Conferences | Events
Merck Millipore Partners with Gyros to Develop, Manufacture and Commercialize Kits on the Gyrolab Immunoassay Platform
Simple, automated, nanoliter-scale assays requiring as little as 1uL of sample. Ready-to-use kits are fully validated for reliable use in clinical research. Accuracy and precision meet or exceed ELISA performance.
Merck Millipore, the Life Science division of Merck, today announced a partnership with Gyros AB to develop, manufacture and commercialize immunoassay kits for the Gyrolab™ platform. The new, fully validated kits from Merck Millipore will enable clinical researchers and drug developers to generate valuable research data much faster than typical ELISA kits. Traditional ELISAs can consume significant time, sample and reagents. With the fully automated, walk-away system from Gyros, up to 560 data points can be generated in a run.
"We are very pleased to be able to partner with Gyros to fill a commercial need to provide immunoassay kits requiring only nanoliter reagent volume on a truly high-throughput platform," says Jehangir Mistry, PhD, General Manager, Multiplex & Immunoassays at Merck Millipore.
Because the Gyrolab™ platform employs microfluidic technology with parallel processing, it offers many advantages over traditional assays in addition to reagent and time savings. Gyrolab™ assays provide (1) accuracy over a four-log dynamic range, compared to two logs for ELISAs (2) elimination of cross-talk and plate position artifacts and (3) simplified sample prep with reduced matrix interference.
Gyros' Global Marketing Director Maria Hjortsmark commented: "The Gyrolab™ platform revolutionizes immunoassays, enabling scientists to analyze a large number of samples in parallel, at nanoliter scale and using a fully automated system. We are delighted that Merck Millipore has now chosen to work with us to develop off-the-shelf kits, to further reduce time to results, freeing up analyst time and offering an easier route to robust, reproducible data."